NCT03439891 - Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 16, 2018

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions

Stage III Hepatocellular Carcinoma AJCC v8Stage IIIA Hepatocellular Carcinoma AJCC v8Stage IIIB Hepatocellular Carcinoma AJCC v7Stage IIIC Hepatocellular Carcinoma AJCC v7Stage IV Hepatocellular Carcinoma AJCC v8Stage IVA Hepatocellular Carcinoma AJCC v8Stage IVB Hepatocellular Carcinoma AJCC v8

Interventions

BIOLOGICAL

Nivolumab

Given IV

DRUG

Sorafenib

Given PO

Trial Locations (2)

94143

University of California, San Francisco, San Francisco

95817

University of California, Davis, Sacramento